Difference between revisions of "Moclobemide-maprotiline"
From Psychiatrienet
| Line 7: | Line 7: | ||
* '''Day 8:''' stop administration of moclobemide. | * '''Day 8:''' stop administration of moclobemide. | ||
| start = | | start = | ||
| − | * | + | * No wash-out period is necessary. |
| − | * '''Day | + | * '''Day 9:''' start maprotiline after this period in a normal dosage of 25-75 mg/day. |
* “Start low, go slow” is not required, but caution is necessary.}} | * “Start low, go slow” is not required, but caution is necessary.}} | ||
Revision as of 14:09, 8 May 2009
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from moclobemide to maprotiline.[1] [2]
Stop moclobemide - Before day 0: gradually reduce dosage of moclobemide to a maximum of 300 mg/day.
- Day 1: reduce the dosage of moclobemide to 150 mg/day.
- Day 8: stop administration of moclobemide.
Start maprotiline- No wash-out period is necessary.
- Day 9: start maprotiline after this period in a normal dosage of 25-75 mg/day.
- “Start low, go slow” is not required, but caution is necessary.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
